Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Share-based Compensation: 2023-2025

Historic Share-based Compensation for Immunocore Holdings (IMCR) over the last 3 years, with Sep 2025 value amounting to $9.8 million.

  • Immunocore Holdings' Share-based Compensation rose 49.98% to $9.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.0 million, marking a year-over-year increase of 16.24%. This contributed to the annual value of $34.2 million for FY2024, which is 5.30% up from last year.
  • Latest data reveals that Immunocore Holdings reported Share-based Compensation of $9.8 million as of Q3 2025, which was down 1.95% from $10.0 million recorded in Q2 2025.
  • In the past 5 years, Immunocore Holdings' Share-based Compensation ranged from a high of $10.0 million in Q2 2025 and a low of $6.6 million during Q3 2024.
  • In the last 3 years, Immunocore Holdings' Share-based Compensation had a median value of $8.8 million in 2023 and averaged $8.7 million.
  • Per our database at Business Quant, Immunocore Holdings' Share-based Compensation declined by 20.00% in 2024 and then spiked by 49.98% in 2025.
  • Over the past 3 years, Immunocore Holdings' Share-based Compensation (Quarterly) stood at $7.2 million in 2023, then increased by 20.53% to $8.7 million in 2024, then soared by 49.98% to $9.8 million in 2025.
  • Its Share-based Compensation stands at $9.8 million for Q3 2025, versus $10.0 million for Q2 2025 and $9.5 million for Q1 2025.